Fluctuations in levels of antiphospholipid antibodies and increased coagulation activation markers in normal andheparin-treated antiphospholipid syndrome pregnancies

Abstract

Antiphospholipidantibodies (aPL) are associated with anincreased risk of thrombosis and recurrent miscarriage. Weassessed levels of coagulation activation markers and aPL during normal pregnancy and in women with the antiphospholipid syndrome (aPS). Fluctuations in aPL levels were observed in all patients with aPS. No particular pattern of antibody positivity, or fluctuation in aPL level,was associated with poor pregnancy outcome. A significant increase was observed in levels of factor XIIa(FXIIa; P 0.001), factor VIIa (FVIIa, P 0.001), thrombin antithrombin complexes (TAT; P 0.001), prothrombin fragment F1.2 (F1.2; P 0.001) and D-dimer (DD; P 0.05) during normalpregnancy. Factor VIIa, TAT, F1.2 and DD increased significantly before 20 weeks gestation, while a statistically significant increase in FXIIa levels was first detected between weeks 20 and 30 of gestation. In pregnant women with aPS, increases in FXIIa were similar to those in normal pregnancy, but increasedFVIIa levels were not observed until after 30 weeks gestation.Similar to normal pregnancy, increased levels of TATandF1.2 were detected in aPS pregnancies before 20 weeks gestation, but increased DD were not observed until afterweek 20. Surprisingly, women with aPS receiving low molecular weight heparin prophylaxis had significantly higher (P 0.02) levels of TAT (median 8.6; interquartile range (IQR) 6.5–20.8) between weeks 20 and 30 of gestation compared to the normal pregnant population (median 5.9; IQR 4.7–7.9), thus indicating increased thrombin generationin women with aPS in mid-pregnancy.

Keywords

coagulation activation markers antiphospholipid antibody pregnancy heparin

Get full access to this article

View all access options for this article.

References

Khamashta MA , Cuadrado MJ , Mujic F , Taub NA , Hunt BJ , Hughes GR . The management of thrombosis in the antiphospholipid-antibody syndrome . New Engl J Med 1995; 332: 993–997 .

Rand JH , Wu XX , Andree HA et al. Pregnancy loss in the antiphospholipid-antibody syndrome— a possible thrombogenic mechanism . New Engl J Med 1997; 337: 154–160 .

Ginsberg JS , Wells PS , Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism . Blood 1995; 86: 3685–3691 .

Delorme MA , Burrows RF , Ofosu FA , Andrew M . Thrombin regulation in mother and fetus during pregnancy . Semin ThrombHemost 1992; 18: 81–90 .

Stirling Y , Woolf L , North WR , Seghatchian MJ , Meade TW . Haemostasis in normal pregnancy . Thromb Haemost 1984; 52: 176–182 .

Clark P , Brennand J , Conkie JA , McCall F , Greer IA , Walker ID . Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy . Thromb Haemost 1998; 79: 1166–1170 .

Walker ID . Thrombophilia in pregnancy . J Clin Pathol 2000; 53: 573–580 .

Donohoe S , Kingdom JC , Mackie IJ . Affinity purified human anti-phospholipid antibodies bind normal term placenta . Lupus 1999; 8: 525–531 .

Donohoe S , Kingdom JC , Mackie IJ et al. Ontogeny of β2 glycoprotein I and annexin V in villous placenta of normal and antiphospholipid syndrome pregnancies . Thromb Haemost 2000 (July); 84: 32–38 .

10.

Donohoe S , Mackie I , Machin SJ . Immunolocalisation of TFPI in placental tissue during normal and APS pregnancies .J Autoimmun 2000; 15: A27-A27 (Abstract).

11.

Miller GJ , Esnouf MP , Burgess AI , Cooper JA , Mitchell JP . Risk of coronary heart disease and activation of factorXII in middle-aged men . Arterioscler Thromb Vasc Biol 1997; 17: 2103–2106 .

12.

Kohler HP , Carter AM , Stickland MH , Grant PJ . Levels of activated FXII in survivors of myocardial infarction—association with circulating risk factors and extent of coronary artery disease . Thromb Haemost 1998; 79: 14–18 .

13.

Mitropoulos KA , Martin JC , Burgess AI et al. The increased rate of activation of factor XII in late pregnancy cancontribute to the increased reactivity of factor VII . Thromb Haemost 1990; 63: 349–355 .

14.

Meade TW , Mellows S , Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of theNorthwick Park Heart Study . Lancet 1986; 2: 533–537 .

15.

Mitropoulos KA , Martin JC , Reeves BE , Esnouf MP . The activation of the contact phase of coagulation by physiologic surfaces in plasma: the effect of large negatively charged liposomal vesicles . Blood 1989; 73: 1525–1533 .

16.

Mitropoulos KA , Reeves BE , Miller GJ . The activation offactor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins . Blood Coagul Fibrinol 1993; 4: 943–951 .

17.

Harris EN . Syndrome of the black swan . Br J Rheumatol 1987; 26: 324–326 .

18.

Greaves M , Cohen H , Machin SJ , Mackie I . Guidelines on the investigation and management of the antiphospholipid syndrome . Br J Haematol 2000; 109: 704–715 .

19.

Harris EN . Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group . Am J Clin Pathol 1990; 94: 476–484 .

20.

Donohoe S , Mackie IJ , Isenberg D , Machin SJ . Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome . Br J Haematol 2001; 113: 544–549 .

21.

McNally T , Mackie IJ , Machin SJ , Isenberg DA . Increasedlevels of β 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding anti-bodies are associated with a historyof thromboembolic complications in patients with SLE and primary antiphospholipid syndrome . Br J Rheumatol 1995; 34: 1031–1036 .

22.

Morrissey JH , Macik BG , Neuenschwander PF , Comp PC . Quantitation of activated factor VII levels in plasma using atissue factor mutant selectively deficient in promoting factor VII activation . Blood 1993; 81: 734–744 .

23.

Bremme K , Ostlund E , Almqvist I , Heinonen K , Blomback M . Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium . Obstet Gynecol 1992; 80: 132–137 .

24.

Elias A , Bonfils S , Daoud-Elias M et al. In fluence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin–antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis . Thromb Haemost 1993; 69: 302–305 .

25.

Rai R , Cohen H , Dave M , Regan L . Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospho-lipid antibodies) . Br Med J 1997; 314: 253–257 .

26.

Guerin J , Smith O , White B , Sweetman G , Feighery C , Jackson J . Antibodies to prothrombin in antiphospholipid syndrome and in‘ ammatory disorders . Br J Haematol 1998; 102: 896–902 .

27.

Kwak JY , Barini R , Gilman-Sachs A , Beaman KD , Beer AE . Down-regulation of maternal antiphospholipid antibodies during early preg-nancy and pregnancy outcome . Am J ObstetGynecol 1994; 171: 239–246 .

28.

Topping J , Quenby S , Farquharson R , Malia R , Greaves M . Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome . Hum Reprod 1999; 14: 224–228 .

29.

McNally T , Mackie IJ , Machin SJ , Isenberg DA . Elevated levels of β2glycioprotein-I (β2GPI) inantiphospholipidantibody syndrome are due to increased amounts of β2GPI in association with other plasma constituents . Blood Coagul Fibrinol 1995; 6: 411–416 .

30.

Biasiolo A , Rampazzo P , Brocco T , Barbero F , Rosato A , Pengo V . [Anti-β2 Glycoprotein I-β2 Glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases . Lupus 1999; 8: 121–126 .

31.

Lim KJH , Odukoya OA , Li TC , Cooke ID . Cytokines and immune-endocrine factors in recurrent miscarriage . Hum Reprod Update 1996; 2: 469–481 .

32.

Christiansen OB . A fresh look at the causes and treatments of recurrent miscarriage, especially its immunologicalaspects . Hum Reprod Update 1996; 2: 271–279 .

33.

Ruffatti A , Scapinello MP , Tonetto S et al. Trends in immunoglobulin G anticardiolipin antibodies in ten successful heparin-treated pregnancies . Rheumatol Int 1996; 16: 15–18 .

34.

De Wolf F , Carreras LO , Moerman P , Vermylen J , Van AsscheA , Renaer M . Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant . Am J Obstet Gynecol 1982; 142: 829–834 .

35.

Out HJ , Kooijman CD , Bruinse HW , Derksen RH . Histopathologicalfindings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies . Eur J Obstet Gynecol Reprod Biol 1991; 41: 179–186 .

36.

Salafia CM , Pezzullo JC , Lopez-Zeno JA , Simmens S , Minior VK , Vintzileos AM . Placental pathologic features of preterm preeclampsia . Am J Obstet Gynecol 1995; 173: 1097–1105 .

37.

Salafia CM , Parke AL . Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome . Rheum Dis Clin N Am 1997; 23: 85–97 .

38.

de Moerloose P , Amiral J , Vissac AM , Reber G . Longitudinal study on activated factors XII and VII levels during normal pregnancy . Br J Haematol 1998; 100: 40–44 .

39.

Halbmayer WM , Hopmeier P , Mannhalter C et al. Cl-esterase inhibitor in uncomplicated pregnancy and mild and moderate preeclampsia . Thromb Haemostasis 1991; 65: 134–138 .

40.

Donohoe S , Cardigan RA , Mackie I , Isenberg D , Machin S . Increased FXII activation in patients with the antiphospholipid syndrome . J Autoimmun 2000; 15: A15-A15 . Abstract.

41.

Zangari M , Lockwood CJ , Scher J , Rand JH . Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies . Thromb Res 1997; 85: 177–183 .